Stocks / NASDAQ / Loxo Oncology, Inc.

Loxo Oncology, Inc.

Our Opinion

Loxo Oncology, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.

Supporting Evidence:

The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.

“Loxo Oncology’s novel, potent and selective RET inhibitor demonstrated potent inhibition of RET in enzyme and cellular assays with minimal activity against highly related kinases in animal models.” Read the following article

Company Description

Loxo Oncology, Inc. is a biopharmaceutical company, which develops small molecule therapeutics for the treatment of cancer. Its pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. [Source: MarketWatch]

Company Website: